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Safety is a primary concern of consumers and scientists regarding the devel-
opment and use of genetically engineered agricultural products. Debates
are␣ polarized and could well become more so over such questions as will
genetically modified organisms (GMOs) irreparably harm genetic diversity in
wild relatives and land races? Will they harm human health and ecosystems?
At␣ the same time, there is concern over whether another StarLink™-type case
will hit and hurt not just one company but the entire industry by eroding
public confidence. And the challenge of achieving broadly accepted environ-
mental- and food-safety standards is that much greater for the next generation
of biotech products, for example crops and even fish engineered to produce
drugs and industrial compounds.
At the University of Minnesota’s Institute for Social, Economic, and
Ecological Sustainability (ISEES), our experience in other policy areas leads
us␣ to believe that it is possible to address biosafety issues and realize the
promises of agricultural biotechnology. A coalition of diverse partners have
come together in the National Safety First Initiative with the goal of developing
and instituting industry-wide, publicly trusted, and scientifically reliable safety
standards.
THE INITIATIVE
The Initiative employs a representational, deliberative, and transparent process
grounded in science. There are four fundamental aspects.
• Quick fixes to current biotech debates are not possible. We are convinced
that the first step must be to break from the binary yes-or-no choice on
biotech and food. No easy consensus has eluded others that we can
somehow snatch. There are real differences of perspective on biotech-safety
issues in American society, including within the scientific and business
communities. Our starting point is to acknowledge the existence of these
differences.
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• The Safety First Initiative involves a forum and a process for identifying
differences and then negotiating through them honestly in a collective
effort to develop cross-industry safety standards.
• The Safety First Initiative draws from the history of safety work in various
American industries that involve complex engineering processes. At the
workshop that launched public deliberation of our proposed safety-first
approach, economic historians and safety engineers and analysts reviewed
safety successes and pitfalls from a broad range of industries. We looked at
the steel, lead, aircraft, food manufacturing and nuclear-power industries.
These experts deliberated with biotech and bio-safety experts and
concerned parties from industry, academia, and public-interest groups
on␣ panels and in a variety of break-out groups to make recommendations
to guide proactive safety governance in the recently emerged and diverse
biotechnology industry. We learned that attention to safety has historically
come from strong external pressures from consumers, politicians and
various organizations as well as from enlightened leadership within
industry. Some companies in the United States stuck too long to a “safety-
second” approach that resulted in financial losses, liability problems and
erosion of consumer confidence. And we also learned that in some
companies—either a maverick firm, for example US Steel in the early
1900s, or a coalition of firms and external stakeholders, for example
aircraft manufacturers in the late 1900s—took the lead in placing safety
first as a smart business stratagem that eventually transformed industry
as␣ a whole. Therefore, the Safety First Initiative builds on a time-tested
American approach. It seeks to recreate the systems that are in place in
other industries that developed safety standards with consumer and public
consultation and thus achieved improved safety records and built public
trust of their products.
• The Safety First Initiative is a public/private-sector partnership that is
neither pro-regulatory nor deregulatory.
After remarkably positive feedback and interest expressed by the wide
spectrum of participants in our 2001 workshop, a coalition emerged from
business, the public-interest, community, and academe to plan and conduct
an␣ innovative process for negotiating industry-wide safety standards.
OBJECTIVES
The Safety First Initiative intends to draw up the nation’s first cross-industry
and publicly trusted standards for designing, producing, and monitoring biotech
products, with safety a primary criterion throughout: from the early stages of
designing a genetic construct at the lab bench through R&D and the elaborate
processes involved in developing a stable GM variety or line through pre-
market regulatory approval and post-market monitoring. Long-established
principles of safety engineering offer a series of logical and well tested steps
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for␣ addressing contentious and complex issues involved in the manufacture
of␣ safe products.
The Safety First Initiative plans to organize cross-sectoral working groups
that will negotiate similar elements of environmental and food-safety standards
for GMOs in agriculture and aquaculture. These elements are as follows.
• Safety-criteria setting. These standards set the safety objectives from which
follow the safety standards. It involves systemic risk analysis and planning
to reduce risk, emphasizing what can be done to build safety from the
outset to the design of genetic constructs and the choice of traits to modify.
• Verification standards. Prior to marketing, these standards address whether
the product meets safety objectives to reasonable, measurable levels.
Verification standards drive the design of scientific, reliable tests to fully
challenge the product, drawing on the best available science from all
relevant fields. Obviously, verification standards also must address
questions about quality and type of data obtained from these verification
tests.
• Follow-up standards. These address uncertainty, recognizing that even
the␣ best criteria and verification standards cannot anticipate all problems.
Therefore scrupulous monitoring of a product in all its uses is needed,
with the monitoring system designed to be practical and cost effective,
targeting the most likely problematical areas. Such an approach fosters
timely discovery of problems and early application of corrective measures.
• Safety leadership standards. These aim to ensure that the prior three types
of standards are implemented consistently and properly. This involves, for
example, establishment of rigorously trained and independently certified
safety engineers who would be valued employees of companies as well as
in government regulatory agencies. Such professionals—with independent
certification—exist in other industries, for example in companies that
manufacture and install complex aircraft components. And safety-
conscious leadership at all management levels is an essential element.
Although pioneering firms have not received appropriate recognition for
their efforts, we recognize that some agricultural biotech companies have
already established one or more of these elements, providing the foundation
for␣ an industry-wide program of safety leadership.
CAVEATS
Two important caveats affect the negotiation of these standards. First is the
issue of what is safe enough. One hundred percent safety can never be
guaranteed. Defining what is safe enough will be a major objective of the
representative deliberative process, involving negotiating an acceptable balance
point between potential benefits—or, preferably, documented benefits—
and␣ the␣ assurance level of safety for a given GM product. The second caveat
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involves the distinction between non-living and living materials, because
we␣ are␣ drawing on safety-engineering principles for manufactured non-living
products. Qualitative differences exist between products derived from living
organisms—such as foods derived from GMOs—and those from inanimate
source materials. Our challenge is to draw on the history and rigorous methods
of safety engineering of inanimate materials and apply lessons, where
appropriate, to biological products.
How does this relate to HACCP1? There are several overlaps, and we plan
to␣ carefully study the HACCP process—which was designed to address safety
issues in foods—focusing on food production from biological materials.
INCLUSIVE DELIBERATIONS
The partners in our coalition recognize that achieving public trust in GM
products that will be vetted through safety standards that will emerge from
the␣ initiative will entail important roles for the government and the public.
For␣ instance, government oversight should reinforce motivation for industry
safety programs to be scientifically reliable, responsible, and responsive.
Regarding public participation, the initiative involves transparent and inclusive
deliberation, taking a cue from the airline industry where cross-sectoral
working groups have been organized, including participants from business,
consumer and public-interest groups and government agencies. Over a two-
year␣ period standards and procedures for industry-wide safety programs were
negotiated, which, because there had been such an inclusive deliberative
process, were endorsed by all parties. Companies adopted the standards and,
in␣ fact, went to their regulatory agency, the FAA, who rapidly incorporated
them into the details of their regulations.
Similar inclusive deliberations have also been used for periodic review to
update industry-wide standards in light of new information. Thus, the biotech
industry can benefit from other engineering industries that have discovered
that␣ an open process grounded in science wins every time—in the long term
reducing costs of product development and approval.
The Initiative’s Executive Advisory Board is a partnership of prominent
leaders of diverse private and public sectors. The co-chairs are Chuck Johnson,
retired vice-president of DuPont, formerly with Pioneer HiBred, and Tim
Penny,␣ former US Congressman and presently director of the Humphrey Policy
Center here at the University of Minnesota. Other members of the board are
John Block, former US Secretary of Agriculture, Margaret Mellon, the program
director of the food and environment program at the Union of Concerned
Scientists, Vin Webber, former Congressman and co-director of Empower
America, and John Woodhouse who recently retired as CEO of Sysco
Corporation. The charge of the Executive Advisory Board is to provide
1Hazards Analysis and Critical Control Points.
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advice␣ on planning and oversight for the Steering Committee and the Initiative’s
outcomes. They are providing important advice on the substantive and
procedural aspects of a plan for moving forward.
On the Steering Committee are leaders from large companies such as
Syngenta and DuPont, from small new biotech companies including ProdiGene,
and from the very small Cape AquaCulture Technologies. It is important that
the standards that emerge from this initiative do not have an exclusionary effect
on small biotech firms. When approached, the president of Cape AquaCulture
Technologies, Bob Curtis, was immediately interested as it was an opportunity
to get over a difficulty that his company was in. Because of recent media focus
on consumer jitters over genetically engineered salmon that are expected to
receive government approval, venture capitalists and other investors have been
uncertain about investing in the biotechnology that he would like to apply in
fish. He was looking for a way to show that his is a responsible company, and,
by contributing to the development of standards that would be applied across
industry, he would have a means of allaying fears. And, interestingly, some
investors have quietly been checking in with us and asking to stay apprised,
because they seek publicly vetted procedures for guiding their decisions.
The Steering Committee includes representatives from the world of
commodity farming, from organic farming, consumer organizations, other
NGOs, and academia. Jean Kinsey, director of the Food Retail Industry Center
and professor of applied economics at the University of Minnesota—a speaker
at this conference—is one of the members of the steering committee, as is John
Howard—also a speaker—chief scientific officer at ProdiGene. The members
of␣ the Steering Committee are committed to furthering the Safety First Initiative
and to maintaining communication links with the communities they represent.
Each has important experience and perspectives that will shape and the
Initiative’s work and outputs. The committee is charged to provide oversight
on␣ the cross-representational working groups—including the negotiation
process—and their outputs. The Steering Committee will carefully review
the␣ standards drawn up by the working groups, and problems will be returned
to the working groups. Ultimately the Executive Advisory Board will review
the␣ standards before release.
MODUS OPERANDI
The Executive Advisory Board and Steering Committee convened for the first
time on April 22, 2002, to initiate a draft plan for developing industry-wide
safety standards and discuss modus operandi.
The cross-sectoral working-group negotiations will focus on (i) the
broadest␣ general safety principles applicable to the range of GM products
that␣ the Initiative will address, and on (ii) product-specific standards that
will␣ be tailored to issues raised by particular GM products that the initiative
will address.
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Each company that adopts standards for these two levels will accordingly
create their own standards for use at the company-project level. We will not
be␣ involved in how they decide to meet these standards.
The ISEES staff will provide the Safety First Initiative with administrative and
managerial support and will provide professional facilitation at all meetings.
Some staff members, including the author, have expertise in biosafety science
and technical aspects, and we work closely with a leading system safety
engineer from the aircraft industry. The ISEES staff will work with the Steering
Committee to identify, invite and bring together working group members. We
envision four working groups meeting in parallel, with communication between
groups and with the Initiative leadership. The reason for four main working
groups relates to the four central elements described above. Each working
group will have sub-working groups on specific products.
The working groups will be cross-sectoral teams with various technical
expertise but will also represent consumer interests. Furthermore, they will put
themselves in the shoes of a company safety engineer: how should the product
be designed to ensure maximum safety from the outset—what will be the R&D
needs—what will be the government-approval needs—and what aspects will
ensure broad public acceptance?
There were two major outcomes from the April 22, 2002, meeting. The Board
and Steering Committee provided a frank critique of our draft plan, offering
various personal perspectives. After working through some questions and mid-
course corrections, they gave strong and clear endorsement of the Initiative’s
goals and substance, and the proposed approach: substance in terms of the goal
of developing industry-wide safety standards, and process in terms of cross-
sectoral transparent deliberation. The second major outcome was the consensus
to focus the Initiative on two types of GM products:
• crops providing non-food products, from pharmaceuticals to industrial
materials (with the possibility that this might include farm animals), and
• food products from genetically modified fish and shellfish.
Over the next 6 months the Initiative will concentrate on forming and
convening the working groups and thus move into the functional phase of
negotiating safety standards.
